Home Consultants Dr Martin Hogg

Rutherford Location

Leave a message


  • Breast
  • Gynaecological


Dr Martin Hogg is a Consultant Clinical Oncologist who specialises in breast and gynaecological cancers and has twenty years of experience treating patients.  His interests include clinical trials, technical radiotherapy and targeted therapies. He's served two terms as Clinical Director at Rosemere Cancer Centre and as Head of service on the Faculty Board of the Royal College of Radiologists.

Dr Hogg is currently chemotherapy lead at East Lancashire Hospitals NHS Trust and holds an interest in patient-centric care as well as the health and well being of colleagues. He is currently Deputy Chair of the North West Clinical Senate providing and MAC Chair at the Rutherford Cancer Centre North West.

Professional bodies

  • Deputy Chair NW Clinical Senate
  • Member of RCR Support and Well Being Group



  • MA
  • Oxon
  • BM
  • BS
  • FRCR


  • Royal College of Radiologists


Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.

Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, Barrett-Lee P, Bliss P, Bloomfield D, Bowen J, Donovan E, Goodman A, Harnett A, Hogg M, Kumar S, Passant H, Quigley M, Sherwin L, Stewart A, Syndikus I, Tremlett J, Tsang Y, Venables K, Wheatley D, Bliss JM, Yarnold JR.

J Clin Oncol. 2020 Oct 1;38(28):3261-3272. doi: 10.1200/JCO.19.02750. Epub 2020 Jul 14.

PMID: 32663119 Free PMC article. Clinical Trial.


Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell NS; MRC SUPREMO trial UK investigators.

Lancet Oncol. 2018 Nov;19(11):1516-1529. doi: 10.1016/S1470-2045(18)30515-1. Epub 2018 Oct 15.

PMID: 30337220 Clinical Trial.


Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators.

N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5.

PMID: 28581356 Free PMC article. Clinical Trial.


Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.

Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, Mitchell CL, Badea D, Moon S, Hogg M, Hadjiyiannakis D, Clancy T, Schlecht H, Woodward ER, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Lalloo FI, Harkness EF, Evans DGR.

Eur J Hum Genet. 2020 Nov;28(11):1541-1547. doi: 10.1038/s41431-020-0692-y. Epub 2020 Jul 10.

PMID: 32651552


Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.

Saunders MP, Hogg M, Carrington B, Sjursen AM, Allen J, Beech J, Swindell R, Valle JW.

Br J Cancer. 2004 Oct 18;91(8):1447-52. doi: 10.1038/sj.bjc.6602173.

PMID: 15452550 Free PMC article. Clinical Trial.


Chloride influx in human leucocytes: a triple-isotope technique for the assessment of chloride transporters.

Hogg M, Ng LL, Davies JE.

Clin Sci (Lond). 1991 Sep;81(3):405-12. doi: 10.1042/cs0810405.

PMID: 1655344


ASCO 21: Abstract (e13019)Vinorelbine and capecitabine in metastatic breast cancer following CD4/6 inhibitors Mugisa T, Smitri Gaur ,Hogg M



  1. Dr Martin Hogg does not hold a share or financial interest in the Rutherford Cancer Centres or another Rutherford Health plc company.
  2. Dr Martin Hogg does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Rutherford Health plc company.
  3. Dr Martin Hogg does not hold any paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Rutherford Health plc.

Get in Touch

If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or

Our Trusted Healthcare Partners